Vai al contenuto principale
xMedica

NCT07439653ClinicalTrials.gov

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Fase 1 / Fase 2155 partecipanti ricercati9 centri1 paese

Categorie

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-02-27; recorded start 2026-03-31
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Not stated: Open label (no blinding)Masking is recorded as none (open label)
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 9 other studies in this databaseCounted from the lead sponsor named in the record (TORL Biotherapeutics, LLC)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Non-randomised allocation

  • Blinding0/20

    Open-label

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 3 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleSMALL

A small study: 155 participants (target), run at 9 sites.

How this score is built
  • Enrolment21/40

    155 participants (target)

  • Site count6/25

    3 sites

  • Country count0/15

    Single country

  • Planned duration9/10

    Planned over about 43 months

  • Sponsor scale3/10

    TORL Biotherapeutics, LLC has led 10 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Patologie

  • Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Idoneità

Idoneità
SessoTutti
Età18 Years – Nessun massimo
Volontari saniNo

Idoneità come riportata nel registro

Inclusion Criteria: * Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT. * Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2. * At least 1 measurable lesion per Lugano criteria. * Tumor tissue is available. * Adequate organ function Exclusion Criteria: * T-cell lymphoma * CLL or SL * Burkitt lymphoma and high-grade B-cell lymphoma * CNS involvement * Peripheral neuropathy \> Grade 2 * Uncontrolled medical conditions * Viral infections

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studioInterventistico
FaseFase 1 / Fase 2
AssegnazioneNon randomizzata
Modello di interventoSEQUENTIAL
Finalità principaleTREATMENT
MascheramentoNONE (0)
Arruolamento155 partecipanti ricercati

Sponsor e collaboratori

  • TORL Biotherapeutics, LLC Sponsor

Bracci e interventi

  • Part 1: Monotherapy Dose EscalationEXPERIMENTAL

    TORL-5-700 Administered once every three weeks

  • Part 2: Monotherapy ExpansionEXPERIMENTAL

    TORL-5-700 at MTD/RP2D Administered once every three weeks

  • Part 3: Combination EvaluationEXPERIMENTAL

    TORL-5-700 at MTD/RP2D Administered once every three weeks in combination with another agent

Interventi

  • Farmaco TORL-5-700

    Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks

  • Farmaco TORL-5-700 at MTD/RP2D

    Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) Administered once every three weeks

  • Farmaco TORL-5-700 at MTD/RP2D in combination with another agent

    Part 3: Combination Evaluation - TORL-5-700 at MTD/RP2D administered every three weeks in combination with another agent

Esiti misurati

  1. Esito primario

    Evaluate the safety of TORL-5-700 as a monotherapy

    Assessment of adverse events according to NCI-CTCAE Version 5.0

    Orizzonte temporale though study completion, an average of 2.5 years

  2. Esito primario

    Assess the antitumor activity of TORL-5-700 as monotherapy

    Assess the antitumor activity of TORL-5-700 using Cheson (2014) disease grading criteria

    Orizzonte temporale though study completion, an average of 2.5 years

  3. Esito primario

    Evaluate the safety of TORL-5-700 in combination with other agents

    Assessment of adverse events according to NCI-CTCAE Version 5.0

    Orizzonte temporale though study completion, an average of 2.5 years

  4. Esito primario

    Determine the Maximum Tolerated Dose (MTD)

    Determine the MTD by assessing Protocol defined Dose Limiting Toxicities (DLT)

    Orizzonte temporale 21 days from the start of treatment

  5. Esito primario

    Determine the Recommended Phase 2 Dose (RP2D)

    Determine the RP2D by assessing Protocol defined Dose Limiting Toxicities

    Orizzonte temporale 21 days from the start of treatment

  6. Esito secondario

    Maximum Serum Concentration of TORL-5-700 (Cmax)

    Pk assessment

    Orizzonte temporale though end of study treatment, an average of 5 months

  7. Esito secondario

    Maximum Serum Concentration of TORL-5-700 (Cmax) in combination with other agents

    Pk assessment

    Orizzonte temporale though end of study treatment, an average of 5 months

  8. Esito secondario

    Terminal Half-life (t1/2) of Serum TORL-5-700

    Pk assessment

    Orizzonte temporale though end of study treatment, an average of 5 months

  9. Esito secondario

    Terminal Half-life (t1/2) of Serum TORL-5-700 in combination with other agents

    Pk assessment

    Orizzonte temporale though end of study treatment, an average of 5 months

  10. Esito secondario

    Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration

    Pk assessment

    Orizzonte temporale though end of study treatment, an average of 5 months

  11. Esito secondario

    Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration in combination with other agents

    Pk assessment

    Orizzonte temporale though end of study treatment, an average of 5 months

  12. Esito secondario

    Clearance (CL) of TORL-5-700

    Pk assessment

    Orizzonte temporale though end of study treatment, an average of 5 months

  13. Esito secondario

    Clearance (CL) of TORL-5-700 in combination with other agents

    Pk assessment

    Orizzonte temporale though end of study treatment, an average of 5 months

  14. Esito secondario

    Volume of distribution of TORL-5-700

    PK assessment

    Orizzonte temporale though end of study treatment, an average of 5 months

  15. Esito secondario

    Volume of distribution of TORL-5-700 in combination with other agents

    PK assessment

    Orizzonte temporale though end of study treatment, an average of 5 months

  16. Esito secondario

    Immunogenicity of TORL-5-700

    Immunogenicity will be measured by incidence of treatment emergent ADAs

    Orizzonte temporale though end of study treatment, an average of 5 months

  17. Esito secondario

    Immunogenicity of TORL-5-700 in combination with other agents

    Immunogenicity will be measured by incidence of treatment emergent ADAs

    Orizzonte temporale though end of study treatment, an average of 5 months

  18. Esito secondario

    Assess the preliminary antitumor activity of TORL-5-700 in combination with other agents

    Assess the antitumor activity of TORL-5-700 in combination with other agents using Cheson (2014) disease grading criteria

    Orizzonte temporale though study completion, an average of 2.5 years

Date

Date
Data di inizio31 marzo 2026 (effettiva)
Conclusione primaria31 marzo 2029 (stimata)
Conclusione30 settembre 2029 (stimata)
Prima pubblicazione27 febbraio 2026 (effettiva)
Ultimo aggiornamento28 settembre 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltaagosto 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

9 centri stanno reclutando

United States

United States
StrutturaCittàStato o regioneStato
University of Texas Southwestern Medical CenterDallasTexasIn reclutamento
Providence Medical FoundationFullertonCaliforniaIn reclutamento
University of Iowa Health CareIowa CityIowaIn reclutamento
Cancer and Blood Specialty Clinic, Los AlamitosLos AlamitosCaliforniaIn reclutamento
University of California Miami, Sylvester Comprehensive Cancer CenterMiamiFloridaIn reclutamento
Sarah Cannon Research InstituteNashvilleTennesseeIn reclutamento
UCLASanta MonicaCaliforniaIn reclutamento
Stanford UniversityStanfordCaliforniaIn reclutamento
Cancer Center of Kansas, WichitaWichitaKansasIn reclutamento

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

  1. 28 settembre 2026

    Centro aggiunto

    3 sites added (9 total)

    69

  2. 24 agosto 2026

    Centro aggiunto

    3 sites added (6 total)

    36